"Calquence plus venetoclax is the first and only all-oral combination treatment option with a second-generation BTK inhibitor ...

The combination of Bayer's mineralocorticoid receptor antagonist (MRA) finerenone and Boehringer Ingelheim and Eli Lilly's ...

In another sign of recovery in digital health investing, Omada Health has priced an initial public offering (IPO) of $19 per ...

Zaynich is based on cefepime, a well-established beta-lactam antibiotic, combined with a novel beta-lactamase inhibitor ...

Uniting over 600 industry experts this September 22-25, the 15 th World Clinical Biomarkers & Companion Diagnostics (CDx) ...

A long-acting medicine developed by Novo Nordisk has been recommended as a treatment option for young people with growth ...

Added to that, 23andMe suffered a massive data breach in 2023 that resulted in information from about 7 million people being ...

It is the first fundraising effort at Neuralink since its $280 million Series D round in 2023 and brings the company's total ...

The tantalising development has been reported by researchers at the Peter Doherty Institute for Infection and Immunity in ...

Citylabs 4.0, now open in the heart of Manchester’s Knowledge Quarter on the Oxford Road Corridor, was built with exactly ...

The FDA is moving at breakneck speed to roll out a generative artificial intelligence (AI) tool for speeding up regulatory ...

Europe follows a similar pattern, with data from the EU Clinical Trials Information System (CTIS) estimating that less than 0 ...